Methods for diagnosis using anti-cytokine receptor antibodies
AssigneeEarly Detection, LLC
InventorDeborah Adcock
Life of this patent
Estimating the term…
Loading patent…
AssigneeEarly Detection, LLC
InventorDeborah Adcock
Estimating the term…
Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is injected into a patient with a tumor, or suspected tumor, or with any disease associated with STNF-1/STNF-2. The patient is then imaged using standard nuclear imaging equipment to detect areas or sites of concentration of the radiolabel and/or receptor/inhibitor and/or antigen. By screening for cancer by the substances it produces, using an injected antibody to that substance with a tracer attached to it, one can detect cancer at a very early stage, potentially even microscopically.
A method for diagnosing inflammation or cancer comprising administering to a patient an effective amount of a labeled antibody or labeled binding ligand to a cytokine or cytokine receptor and imaging the patient to detect bound antibody or labeled binding ligand.
A kit comprising an effective dosage amount of labeled humanized monoclonal antibodies or labeled binding ligand to a cytokine or cytokine receptor to image cancer or inflammation in a patient, in a pharmaceutically acceptable carrier for intravenous administration.
Dependencies are inferred from the claim text.